Next generation cancer immunotherapies

non-conventional antigens
to reshape tumor immunity

Our team is focused on biotechnology researches, check our work !

Vision & Mission

Combining cancer vaccines
and T-cell therapies

ErVimmune develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.

We are dedicated to discover more accurate tumor epitopes that are shared between patients. We focus on non-conventional epitopes derived from endogenous retroviruses (HERVs).

Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.

recent news

from ErVimmune

About ErVimmune

Medical research and development, in particular the development of new families of tumour antigens.

Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.

Useful links

> Publications & abstracts

> Recent news

> Legal notice


> Home

> About us

> Sciences

> Investors

> Join us

> Contact



+33 6 67 67 44 97

© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go